Baidu
map

Clin Mol Allergy:亚洲过敏性鼻炎和荨麻疹选择优化的第二代抗组胺药物

2017-11-18 AlexYang MedSci原创

在世界上许多地方,过敏性疾病数量正在增加,包括了亚太(APAC)地区。第二代抗组胺药物是治疗过敏性鼻炎和荨麻疹一线药物治疗选择。国际指南描述了这些条件下的治疗过程;然而,临床专家认为根据病人的资料,需要额外的对治疗进行调整。最近,有研究人员邀请了来自APAC地区(香港地区、马来西亚、菲律宾、新加坡、泰国和越南)的专家,进行了旨在描述当对患有过敏性鼻炎或者荨麻疹病人确定优化的第二代抗组胺药物时,所存

在世界上许多地方,过敏性疾病数量正在增加,包括了亚太(APAC)地区。第二代抗组胺药物是治疗过敏性鼻炎和荨麻疹一线药物治疗选择。国际指南描述了这些条件下的治疗过程;然而,临床专家认为根据病人的资料,需要额外的对治疗进行调整。最近,有研究人员邀请了来自APAC地区(香港地区、马来西亚、菲律宾、新加坡、泰国和越南)的专家,进行了旨在描述当对患有过敏性鼻炎或者荨麻疹病人确定优化的第二代抗组胺药物时,所存在的未满足的需求、实际问题、挑战和关键决定因素的研究。

研究发现,临床专家认可这些疾病诊断的额外工具的需要和抗组胺药物作为一种单独的药物具有所有的偏向特性。在治疗中的挑战包括了临床医生的缺乏和病人的意识、顺从性和经济限制以及特殊病人群体的治疗,比如那些具有伴发病的病人。优化的第二代抗组胺药物的选择依赖许多因素,尤其是药物的安全性和治疗效果,以及对心理作用和镇静作用的影响。一些特定国家的考虑还包括了药物的可利用性和经济性。调查结果阐释了比拉斯汀作为一种偏向性选择,具有高效性和安全性,对特定病人群体和缺乏镇静作用适用。

最后,研究人员指出,在过敏专家、皮肤科医生和耳鼻喉科专家中对国际指南的认可是存在的,但是,在全科医生(GPs)中这种认可更低。为了提高意识,进行GPs的过敏教育计划是需要的,并且病人也许能从中受益。对现存的国际指南进行及时的更新以便能够更好的反应对不同病人资料和不同过敏性鼻炎和荨麻疹的合适的治疗选择。

原始出处:

Recto MT, Gabriel MT, Kulthanan K et al. Selecting optimal second-generation antihistamines for allergic rhinitis and urticaria in Asia. Clin Mol Allergy. 1 Nov 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1742146, encodeId=39081e42146b0, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Mon Dec 04 12:01:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046904, encodeId=8ac1204690443, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 15 10:01:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311568, encodeId=c1ac13115682c, content=<a href='/topic/show?id=b53e5560953' target=_blank style='color:#2F92EE;'>#抗组胺药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55609, encryptionId=b53e5560953, topicName=抗组胺药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329037, encodeId=3284132903ec4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355565, encodeId=95d31355565ab, content=<a href='/topic/show?id=0ff310302082' target=_blank style='color:#2F92EE;'>#麻疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103020, encryptionId=0ff310302082, topicName=麻疹)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546067, encodeId=7e84154606e02, content=<a href='/topic/show?id=a6b655610ca' target=_blank style='color:#2F92EE;'>#抗组胺药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55610, encryptionId=a6b655610ca, topicName=抗组胺药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cec13863916, createdName=siiner, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1742146, encodeId=39081e42146b0, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Mon Dec 04 12:01:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046904, encodeId=8ac1204690443, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 15 10:01:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311568, encodeId=c1ac13115682c, content=<a href='/topic/show?id=b53e5560953' target=_blank style='color:#2F92EE;'>#抗组胺药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55609, encryptionId=b53e5560953, topicName=抗组胺药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329037, encodeId=3284132903ec4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355565, encodeId=95d31355565ab, content=<a href='/topic/show?id=0ff310302082' target=_blank style='color:#2F92EE;'>#麻疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103020, encryptionId=0ff310302082, topicName=麻疹)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546067, encodeId=7e84154606e02, content=<a href='/topic/show?id=a6b655610ca' target=_blank style='color:#2F92EE;'>#抗组胺药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55610, encryptionId=a6b655610ca, topicName=抗组胺药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cec13863916, createdName=siiner, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1742146, encodeId=39081e42146b0, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Mon Dec 04 12:01:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046904, encodeId=8ac1204690443, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 15 10:01:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311568, encodeId=c1ac13115682c, content=<a href='/topic/show?id=b53e5560953' target=_blank style='color:#2F92EE;'>#抗组胺药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55609, encryptionId=b53e5560953, topicName=抗组胺药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329037, encodeId=3284132903ec4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355565, encodeId=95d31355565ab, content=<a href='/topic/show?id=0ff310302082' target=_blank style='color:#2F92EE;'>#麻疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103020, encryptionId=0ff310302082, topicName=麻疹)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546067, encodeId=7e84154606e02, content=<a href='/topic/show?id=a6b655610ca' target=_blank style='color:#2F92EE;'>#抗组胺药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55610, encryptionId=a6b655610ca, topicName=抗组胺药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cec13863916, createdName=siiner, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1742146, encodeId=39081e42146b0, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Mon Dec 04 12:01:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046904, encodeId=8ac1204690443, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 15 10:01:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311568, encodeId=c1ac13115682c, content=<a href='/topic/show?id=b53e5560953' target=_blank style='color:#2F92EE;'>#抗组胺药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55609, encryptionId=b53e5560953, topicName=抗组胺药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329037, encodeId=3284132903ec4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355565, encodeId=95d31355565ab, content=<a href='/topic/show?id=0ff310302082' target=_blank style='color:#2F92EE;'>#麻疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103020, encryptionId=0ff310302082, topicName=麻疹)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546067, encodeId=7e84154606e02, content=<a href='/topic/show?id=a6b655610ca' target=_blank style='color:#2F92EE;'>#抗组胺药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55610, encryptionId=a6b655610ca, topicName=抗组胺药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cec13863916, createdName=siiner, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
    2017-11-20 膀胱癌
  5. [GetPortalCommentsPageByObjectIdResponse(id=1742146, encodeId=39081e42146b0, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Mon Dec 04 12:01:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046904, encodeId=8ac1204690443, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 15 10:01:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311568, encodeId=c1ac13115682c, content=<a href='/topic/show?id=b53e5560953' target=_blank style='color:#2F92EE;'>#抗组胺药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55609, encryptionId=b53e5560953, topicName=抗组胺药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329037, encodeId=3284132903ec4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355565, encodeId=95d31355565ab, content=<a href='/topic/show?id=0ff310302082' target=_blank style='color:#2F92EE;'>#麻疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103020, encryptionId=0ff310302082, topicName=麻疹)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546067, encodeId=7e84154606e02, content=<a href='/topic/show?id=a6b655610ca' target=_blank style='color:#2F92EE;'>#抗组胺药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55610, encryptionId=a6b655610ca, topicName=抗组胺药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cec13863916, createdName=siiner, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
    2017-11-20 zhaojie88
  6. [GetPortalCommentsPageByObjectIdResponse(id=1742146, encodeId=39081e42146b0, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Mon Dec 04 12:01:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046904, encodeId=8ac1204690443, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 15 10:01:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311568, encodeId=c1ac13115682c, content=<a href='/topic/show?id=b53e5560953' target=_blank style='color:#2F92EE;'>#抗组胺药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55609, encryptionId=b53e5560953, topicName=抗组胺药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329037, encodeId=3284132903ec4, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355565, encodeId=95d31355565ab, content=<a href='/topic/show?id=0ff310302082' target=_blank style='color:#2F92EE;'>#麻疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103020, encryptionId=0ff310302082, topicName=麻疹)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546067, encodeId=7e84154606e02, content=<a href='/topic/show?id=a6b655610ca' target=_blank style='color:#2F92EE;'>#抗组胺药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55610, encryptionId=a6b655610ca, topicName=抗组胺药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cec13863916, createdName=siiner, createdTime=Mon Nov 20 05:01:00 CST 2017, time=2017-11-20, status=1, ipAttribution=)]

相关资讯

Asia Pac Allergy:永久性过敏性鼻炎患者中,血清25-羟甲基维生素D与血嗜酸细胞负相关

维生素D和过敏性鼻炎(AR)之间的关系仍旧不清楚。最近,有研究人员通过在患有AR的病人中检测血清25-羟甲基维生素D(25(OH)D)调水平、血嗜酸细胞和维生素D受体(VDR)在鼻粘膜上的表达调查了它们之间的关系。研究包括了32名患有永久性过敏性鼻炎的病人和25名对照。研究人员通过酶联免疫试验检测了血清25(OH)D的水平,利用自动化的血液系统检测了外周血嗜酸细胞,然而在下鼻甲粘膜中VDR的表达则

Allergy:患有屋尘螨过敏性鼻炎的病人中,MP29-02可以减少鼻过敏症和鼻介质

鼻过敏症(NHR)是过敏性鼻炎(AR)的一种重要的临床特性。MP29-02(盐酸氮卓斯汀(AZE)和氟替卡松丙酸酯(FP))鼻喷雾在AR中的局部炎症介质和NHR的治疗效果仍旧未知。最近,有研究人员测试了是否MP29-02可以减少AR中的炎症介质和NHR,并且探究了是否该作用的产生归因于鼻上皮屏障功能的恢复。研究人员在28名患有屋尘螨(HDM)AR的病人中进行了为期4周的双盲安慰剂-对照MP29-0

J Allergy Clin Immunol:过敏性鼻炎中,组织胺和辅助性T细胞因子能促使上皮屏障功能障碍

过敏性鼻炎(AR)是由粘膜炎症鉴定而来的,并且由激活的免疫细胞驱使。在AR中,肥大细胞和TH2细胞也许能够减少上皮障碍的完整性,从而维持了上皮障碍的不完整性。最近,有研究人员调查了组织胺和TH2细胞在AR中促使上皮屏障障碍中的作用。研究人员将原发性鼻上皮细胞(pNECs)的气液界面(ALI)培养物用来测量经上皮电阻,4kDa葡聚糖和紧密连接蛋白mRNA表达的细胞旁通量,并且从健康对照、AR病人和特

Exp Ther Med:糖皮质激素的鼻内使用可缓解过敏性鼻炎中的嗅觉障碍

最近,有研究人员调查了糖皮质激素的干预对患有过敏性鼻炎(AR)小鼠嗅觉障碍的影响。研究人员通过对小鼠进行腹腔内注射和鼻内使用卵清建立了一个AR动物模型,并利用埋藏食物测试来评估嗅觉功能,并且利用苏木精和伊红染色来确定鼻粘膜上的形态变化。另外,研究人员还通过免疫组化技术检测了嗅觉黏膜上的嗅觉标记蛋白(OMP)的表达情况,并且在糖皮质激素使用7天和14天后进行了观察。研究发现,AR小鼠中嗅觉障碍的发生

Mol Med Rep:在过敏性鼻炎中白介素-37表达的减少和它的抗炎症作用

白介素-37(IL-37)是IL-1细胞激素家族的一个新成员,并且已经鉴定为一个先天免疫和炎症响应的一个自然的抑制因子。最近,有研究人员进行了旨在确定IL-37在过敏性鼻炎病人中外周血单核细胞(PBMCs)重的表达,并且调查了IL-37对炎症调控因子和CD4+T细胞在AR发病机理中可能的免疫抑制作用。研究人员利用逆转录定量PCR技术和流式细胞术技术,在39名AR病人和43名对照的PBMCs中确定了

Ear Nose Throat J:鼻涂片嗜酸性粒细胞和过敏性鼻炎

最近,有研究人员进行了旨在探究鼻涂片嗜酸性粒细胞数目和过敏性鼻炎(AR)之间的关系,从而确定一个截断值,作为AR诊断的一个标准。同样,研究人员尝试确定了是否该值与明显的症状、持续时间或者类型及AR严重度、或者是共存的哮喘症状相关。研究人员选择了100名病人,并且这些病人具有临床诊断的过敏性鼻炎,另外还包括了一个相同人数的以及年龄和性别匹配的对照组。研究人员在鼻涂片嗜酸性粒细胞每一个高倍视野(HPF

Baidu
map
Baidu
map
Baidu
map